Endometriosis Treatment Market Research Report Information By Drug (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, LNR-IUDs), Treatment Type (Hormonal Therapy, Pain Management), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drugstores, e-Commerce) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. ENDOMETRIOSIS TREATMENT MARKET,BY DRUG

6.1. Overview

6.2. Oral Contraceptives

6.3. Progestins

6.4. NSAIDs

6.5. GnRH Analogues

6.6. LNR-IUDs

6.7. Others

7. ENDOMETRIOSIS TREATMENT MARKET,BY TREATMENT TYPE

7.1. Overview

7.2. Hormonal Therapy

7.3. Pain Management

8. ENDOMETRIOSIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL

8.1. Overview

8.2. Hospital Pharmacies

8.3. Retail Pharmacies

8.4. Drugstores

8.5. e-Commerce

9. ENDOMETRIOSIS TREATMENT MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Endometriosis treatment Market,

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Endometriosis treatment Market,

10.7. Key developments and Growth Strategies

10.7.1. New ProductLaunch/Service Deployment

10.7.2. Merger &Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income,2022

10.8.2. Major Players R&D Expenditure.2022

11. COMPANY PROFILES

11.1. Akorn, Incorporated (U.S.)

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Pfizer Inc. (U.S.)

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. GlaxoSmithKline plc (U.K.)

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Novartis AG (Switzerland)

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Mylan N.V. (U.S.)

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Teva Pharmaceutical Industries Ltd.(Israel)

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Sanofi (France)

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY)

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. AstraZeneca (U.K.)

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Johnson & Johnson Private Limited (U.S.)

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 ENDOMETRIOSIS TREATMENT MARKET, SYNOPSIS, 2018-2032

TABLE 2 ENDOMETRIOSIS TREATMENT MARKET, ESTIMATES &FORECAST, 2018-2032(USD BILLION)

TABLE 3 ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 4 ENDOMETRIOSIS TREATMENT MARKET,BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 5 ENDOMETRIOSIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: ENDOMETRIOSIS TREATMENT MARKET,BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: ENDOMETRIOSIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 9 US: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 10 US: ENDOMETRIOSIS TREATMENT MARKET,BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 11 US: ENDOMETRIOSIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 12 CANADA: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 13 CANADA: ENDOMETRIOSIS TREATMENT MARKET,BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 14 CANADA: ENDOMETRIOSIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 1 EUROPE: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 2 EUROPE: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 3 EUROPE: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 4 GERMANY: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG,2018-2032 (USD BILLION)

TABLE 5 GERMANY: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 6 GERMANY: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 7 FRANCE: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 8 FRANCE: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 9 FRANCE: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 10 ITALY: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 11 ITALY: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 12 ITALY: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 13 SPAIN: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 14 SPAIN: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 15 SPAIN: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 16 UK: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 17 UK: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 18 UK: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 19 REST OF EUROPE: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 20 REST OF EUROPE: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 21 REST OF EUROPE: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 25 JAPAN: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 26 JAPAN: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 27 JAPAN: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 28 CHINA: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 29 CHINA: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 30 CHINA: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 31 INDIA: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 32 INDIA: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 33 INDIA: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 34 INDIA: ENDOMETRIOSIS TREATMENT MARKET,BY END USER,2018-2032 (USD BILLION)

TABLE 35 AUSTRALIA: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 36 AUSTRALIA: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 37 AUSTRALIA: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 38 SOUTH KOREA: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 39 SOUTH KOREA: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 40 SOUTH KOREA: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 41 SOUTH KOREA: ENDOMETRIOSIS TREATMENT MARKET,BY END USER,2018-2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 43 REST OF ASIA-PACIFIC: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 44 REST OF ASIA-PACIFIC: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 46 REST OF THE WORLD: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 47 REST OF THE WORLD: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 48 MIDDLE EAST: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 49 MIDDLE EAST: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 50 MIDDLE EAST: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 51 AFRICA: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 52 AFRICA: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 53 AFRICA: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 54 AFRICA: ENDOMETRIOSIS TREATMENT MARKET,BY END USER,2018-2032 (USD BILLION)

TABLE 55 LATIN AMERICA: ENDOMETRIOSIS TREATMENT MARKET,BY DRUG, 2018-2032 (USD BILLION)

TABLE 56 LATIN AMERICA: ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD BILLION)

TABLE 57 LATIN AMERICA: ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE ENDOMETRIOSIS TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE ENDOMETRIOSIS TREATMENT MARKET

FIGURE 4 ENDOMETRIOSIS TREATMENT MARKET, SHARE (%), BY DRUG, 2022

FIGURE 5 ENDOMETRIOSIS TREATMENT MARKET, SHARE (%), BY TREATMENT TYPE, 2022

FIGURE 6 ENDOMETRIOSIS TREATMENT MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022

FIGURE 7 ENDOMETRIOSIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 NORTH AMERICA: ENDOMETRIOSIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 EUROPE: ENDOMETRIOSIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 ASIA-PACIFIC: ENDOMETRIOSIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 REST OF THE WORLD: ENDOMETRIOSIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 12 ENDOMETRIOSIS TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 13 AKORN, INCORPORATED (U.S.): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 AKORN, INCORPORATED (U.S.): SWOT ANALYSIS

FIGURE 15 PFIZER INC. (U.S.):FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 PFIZER INC. (U.S.):SWOT ANALYSIS

FIGURE 17 GLAXOSMITHKLINE PLC (U.K.):FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 GLAXOSMITHKLINE PLC (U.K.):SWOT ANALYSIS

FIGURE 19 NOVARTIS AG (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 NOVARTIS AG (SWITZERLAND):SWOT ANALYSIS

FIGURE 21 MYLAN N.V. (U.S.).:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 MYLAN N.V. (U.S.).:SWOT ANALYSIS

FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD.(ISRAEL):FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 TEVA PHARMACEUTICAL INDUSTRIES LTD.(ISRAEL):SWOT ANALYSIS

FIGURE 25 SANOFI (FRANCE): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 SANOFI (FRANCE): SWOT ANALYSIS

FIGURE 27 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY): SWOT ANALYSIS

FIGURE 29 ASTRAZENECA (U.K.): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 ASTRAZENECA (U.K.): SWOT ANALYSIS

FIGURE 31 JOHNSON & JOHNSON PRIVATE LIMITED (U.S.):FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 JOHNSON & JOHNSON PRIVATE LIMITED (U.S.):SWOT ANALYSIS